医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

NMOSD

New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

その他ヘルスバイオテクノロジーヘルスケアヘルス一般眼科医療臨床試験製薬　 TimeLine: Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder New Four-year Data Show Sustained Relapse Reduction NMOSD

2021年10月14日

Chugai’s Enspryng (Satralizumab) Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Chugai’s Enspryng (Satralizumab) Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder Chugai’s Enspryng NMOSD Satralizumab

2021年06月28日

CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: CHMP Recommends EU Approval of Chugai’s Enspryng for Neuromyelitis Optica Spectrum Disorder NMOSD Satralizumab

2021年04月26日

UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)

UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)

バイオテクノロジーヘルスケアマネージド・ケア眼科医療臨床試験製薬　 TimeLine: inebilizumab-cdon Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder NMOSD UPLIZNA

2021年03月24日

Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder NMOSD

2020年12月09日

New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)

New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: New Data of Chugai’s Enspryng NMOSD on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder Satralizumab

2020年09月10日

Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology

Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: NMOSD Positive Results Published in The Lancet Neurology the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder

2020年04月24日